 AML which arises from a pre @-@ existing myelodysplastic syndrome ( MDS ) or myeloproliferative disease ( so @-@ called secondary AML ) has a worse prognosis , as does treatment @-@ related AML arising after chemotherapy for another previous malignancy . Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities . 
 AML which <a href='uninflect' title='1'><mark>arises</mark></a> from a pre @-@ existing myelodysplastic syndrome ( MDS ) or myeloproliferative disease ( so @-@ called secondary AML ) <a href='got' title='2'><mark>has</mark></a> a worse prognosis , as <a href='uninflect' title='3'><mark>does</mark></a> treatment @-@ related AML arising after chemotherapy for another previous malignancy . Both of these entities are associated with a high rate of unfavorable cytogenetic abnormalities . 
AML which arise from a pre @-@ existing myelodysplastic syndrome ( MDS ) or myeloproliferative disease ( soo @-@ called secondary AML ) got a worse prognosis , as do treatment @-@ related AML arising after chemotherapy for another previous malignancy . Both of these entities r associated with a high rate of unfavorable cytogenetic abnormalities .